What is Hexagon Bio?
Hexagon Bio is a drug discovery company leveraging a novel understanding of natural product evolution. Its interdisciplinary platform integrates data science, genomics, synthetic biology, and automation to identify potent, evolutionarily refined small molecules and their protein targets directly from fungal genomes. The company focuses on developing these discovered molecules into therapeutics aimed at combating human diseases, positioning itself at the intersection of biotechnology and advanced computational analysis.
How much funding has Hexagon Bio raised?
Hexagon Bio has raised a total of $185.3M across 3 funding rounds:
Other Financing Round
$61M
Series A
$47M
Series B
$77.3M
Other Financing Round (2021): $61M with participation from 8VC, Nextech Invest, SoftBank Group, Casdin Capital, Two Sigma Ventures, and The Column Group
Series A (2022): $47M led by The Column Group, 8VC, and Two Sigma Ventures
Series B (2023): $77.3M supported by 8VC, NexTech, The Column Group, and Two Sigma Ventures
Key Investors in Hexagon Bio
8VC
8VC is a leading technology investment firm that backs visionary teams and industry-transforming companies, with a focus on smart enterprise platforms across various sectors including healthcare and Bio-IT.
Nextech Invest
Nextech Invest is a Zurich-based firm dedicated to accelerating precision medicine by identifying transformative cancer medicines and nurturing emerging biotechnology companies worldwide.
The Column Group
The Column Group (TCG) is a venture ecosystem focused on advancing scientific innovation in the life sciences sector, employing an edge-to-edge investment model to nurture early-stage technology platforms and later-stage programs.
What's next for Hexagon Bio?
With the recent Series B financing and significant prior investment, Hexagon Bio is well-positioned for accelerated growth and the advancement of its therapeutic pipeline. The substantial capital raised, particularly the major strategic investment, indicates strong investor confidence in the company's unique approach to drug discovery. This backing will likely fuel further research and development, scale its proprietary platform, and potentially support clinical trials for its lead candidates. The company's trajectory suggests a move towards solidifying its market position and translating its innovative discoveries into tangible treatments.
See full Hexagon Bio company page
